Drugs / PVSRIPO

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT03564782 Jun 2019 → Apr 2022 invasive breast carcinoma Istari Oncology, Inc. Completed No outcome recorded
Phase 13 trials
Phase 1 NCT04125719 Jun 2020 → Oct 2024 melanoma Darell Bigner Withdrawn No outcome recorded
Phase 1 NCT03712358 Nov 2018 → Mar 2021 melanoma Istari Oncology, Inc. Terminated No outcome recorded
Phase 1 NCT01491893 Apr 2012 → Jun 2017 glioblastoma Istari Oncology, Inc. Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT03973879 Feb 2020 → Jan 2024 malignant glioma Darell Bigner Withdrawn No outcome recorded
Phase not stated1 trial
NCT04599647 glioblastoma Istari Oncology, Inc. No longer available No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as PVSRIPO ClinicalTrials.gov intervention name — accepted as the source's own label NCT03564782
5

NCT01491893

NCT03712358

NCT04125719

NCT04599647

NCT03973879

Modality Other / unclassified “PVSRIPO is a non-neurovirulent rhinovirus:poliovirus chimera” PMID 33875611 Apr 2021
Route Other “intratumoral infusion of PVSRIPO” PMID 29943666 Jun 2018